Methylphenidate for the Treatment of Post-COVID Cognitive Dysfunction (Brain Fog).

Autor:	Clark P; Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Rosenberg P; Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Oh ES; Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Parker A; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Vannorsdall T; Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Azola A; Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Nickles E; Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Galiatsatos P; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Malik M; Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jazyk:	angličtina
Zdroj:	Journal of medical cases [J Med Cases] 2024 Aug; Vol. 15 (8), pp. 195-200. Date of Electronic Publication: 2024 Jul 25.
DOI:	10.14740/jmc4254
Abstrakt:	A substantial number of patients develop cognitive dysfunction after contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), significantly contributing to long-coronavirus disease (COVID) morbidity. Despite the urgent and overwhelming clinical need, there are currently no proven interventions to treat post-COVID cognitive dysfunction (PCCD). Psychostimulants like methylphenidate may enhance both noradrenergic and dopaminergic pathways in mesolimbic and pre-frontal areas, thus improving memory and cognition. We present a case series of six patients who were treated at the Johns Hopkins Post-Acute COVID-19 Team (PACT) clinic for PCCD with methylphenidate 5 - 20 mg in the context of routine clinical care and followed for 4 to 8 weeks. Baseline and post-treatment outcomes included subjective cognitive dysfunction and objective performance on a battery devised to measure cognitive dysfunction in long-COVID patients. Three out of the six patients reported subjective improvement with methylphenidate, one patient described it as "notable" and another as "marked" improvement in memory and concentration. We also found significant pre-treatment subjective complaints of cognitive dysfunction; however, formal cognitive assessment scores were not severely impaired. A statistically significant difference in pre and post scores, favoring intervention, was found for the following cognitive assessments: Hopkins verbal learning test (HVLT) immediate recall, HVLT delayed recall and category-cued verbal fluency. The current series demonstrates promising neurocognitive effects of methylphenidate for long-COVID cognitive impairment, particularly in recall and verbal fluency domains. Competing Interests: None to declare. (Copyright 2024, Clark et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu